Long-term Reductions in Monthly Headache Days With Eptinezumab Treatment in Adults With Chronic Migraine: Results From the PREVAIL Study (P12-12.003)
This post-hoc analysis of PREVAIL evaluated the proportion of patients with ≥50% or ≥75% reduction in monthly headache days (MHDs; based on Migraine Disability Assessment [MIDAS]) at Weeks 12 or 24 who sustained that reduction through subsequent 12-week dosing intervals up to Week 84.
Authors
- Scott N. Grossman (ORCID: https://orcid.org/0000-0001-7033-5226)
- N. Kapur
- David Kudrow
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Susanne F. Awad (ORCID: https://orcid.org/0000-0002-5060-7404)
- Foram Patel
- Amaal J. Starling (ORCID: https://orcid.org/0000-0003-1334-1157)
Institutions
- Lundbeck (Denmark) (DK)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- California Medical Clinic for Headache (US)
- Mayo Clinic Hospital (US)
- Lundbeck (Germany) (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211228
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00